The price of Vyant Bio Inc. (NASDAQ:VYNT) shares last traded on Wall Street rose 57.18% to $1.21.
Based on available information, 2 analysts follow Vyant Bio Inc. (NASDAQ:VYNT). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $13.00 and a low of $5.00, we find $9.00. Given the previous closing price of $0.77, this indicates a potential upside of 1068.83 percent. VYNT stock price is now -7.54% away from the 50-day moving average and -64.11% away from the 200-day moving average. The market capitalization of the company currently stands at $7.07M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Among analysts, 0 rate the stock a hold while 2 rate it a buy. Brokers who have rated the stock have averaged $9.00 as their price target over the next twelve months.
.
In other news, Harris Geoffrey E., Director sold 765 shares of the company’s stock on Nov 18. The stock was sold for $1,021 at an average price of $1.33. Upon completion of the transaction, the Director now directly owns 14,019 shares in the company, valued at $16962.99. A total of 3.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VYNT stock. A new stake in Vyant Bio Inc. shares was purchased by CITADEL ADVISORS LLC during the first quarter worth $5,000. TWO SIGMA SECURITIES, LLC invested $5,000 in shares of VYNT during the first quarter. In the first quarter, CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. acquired a new stake in Vyant Bio Inc. valued at approximately $5,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in VYNT for approximately $3,000. MARINER, LLC purchased a new stake in VYNT valued at around $2,000 in the second quarter. In total, there are 24 active investors with 7.70% ownership of the company’s stock.
A candlestick chart of Vyant Bio Inc. (NASDAQ: VYNT) showed a price of $1.4200 on Thursday morning. During the past 12 months, Vyant Bio Inc. has had a low of $0.66 and a high of $9.85. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 1.80, and a quick ratio of 1.80. The fifty day moving average price for VYNT is $1.3102 and a two-hundred day moving average price translates $3.3718 for the stock.
The latest earnings results from Vyant Bio Inc. (NASDAQ: VYNT) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.2, missing analysts’ expectations of -$0.15 by -0.05. This compares to -$0.20 EPS in the same period last year. The company reported revenue of $0.15 million for the quarter, compared to $0.26 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -40.62 percent. For the current quarter, analysts expect VYNT to generate $70k in revenue.
Vyant Bio Inc.(VYNT) Company Profile
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson’s disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson’s Disease. The company is based in Cherry Hill, New Jersey.
